Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Milvexian - (Librexia ACS) | Acute coronary syndromes | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Bristol-Myers Squibb Company | Deucravacitinib - (IM011-127) | Ulcerative colitis (UC) | Phase 2 | Trial Discontinued | oral | Gastroenterology |
| Bristol-Myers Squibb Company | Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9LA) | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Zeposia (ozanimod) - (YELLOWSTONE) | Crohn's disease | Phase 3 | Data Released | Oral | Gastroenterology |
| Bristol-Myers Squibb Company | Sitravatinib and OPDIVO (nivolumab) | Renal cell carcinoma (RCC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Sitravatinib and tislelizumab | Hepatocellular Carcinoma (HCC) / Gastric / Gastroesophageal Junction Cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Milvexian - (AXIOMATIC-SSP) | Stroke prevention (SSP) | Phase 2 | Data Released | Oral | Cardiology |
| Bristol-Myers Squibb Company | REBLOZYL (Luspatercept) - (COMMANDS) | Non-transfusion-dependent beta-thalassemia | Phase 2 | Data Released | Subcutaneous injection | Genetic Disorder |
